World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
112
Citations
111865
World Ranking
788
National Ranking
479

Immunology

D-Index
113
Citations
118101
World Ranking
421
National Ranking
257

Medicine

D-Index
114
Citations
118249
World Ranking
4611
National Ranking
2504

Suzanne L. Topalian publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Suzanne L. Topalian sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 273 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Suzanne L. Topalian D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Suzanne L. Topalian sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 113 D-Index — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2017 - Member of the National Academy of Medicine (NAM)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Suzanne L. Topalian is affiliated with Johns Hopkins University in the United States and has contributed extensively to the field of medicine, with a focus on oncology. Their research spans multiple subfields, including oncology, immunology, pulmonary and respiratory medicine, electrical and electronic engineering, and aerospace engineering.

The primary areas of study and research topics include:

  • Cancer Immunotherapy and Biomarkers
  • Polyomavirus and related diseases
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Antenna Design and Analysis
  • Cutaneous Melanoma Detection and Management
  • Bacteriophages and microbial interactions

Suzanne L. Topalian has published numerous scientific papers, with recurring appearances in well-known venues such as the Journal of Clinical Oncology, Regular and Young Investigator Award Abstracts, Journal for ImmunoTherapy of Cancer, Cancer Research, and Cancer Cell. The venues with the highest frequency of publications include the Journal of Clinical Oncology with 11 publications and the Journal for ImmunoTherapy of Cancer with 7 publications.

Some notable recent papers authored by Suzanne L. Topalian are:

  • Neoadjuvant checkpoint blockade for cancer immunotherapy, 2020, Science
  • Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial, 2020, Journal of Clinical Oncology
  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab, 2023, Journal of Clinical Oncology

Frequent coauthors collaborating with Suzanne L. Topalian include Janis M. Taube, Drew M. Pardoll, William H. Sharfman, Paul Nghiem, and Evan J. Lipson, reflecting interdisciplinary teamwork and a sustained partnership in the research community.

Throughout their career, Suzanne L. Topalian has been recognized by several professional organizations. Notably, they were named a Member of the National Academy of Medicine in 2017 and hold membership in the Association of American Physicians.

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Immune checkpoint blockade: a common denominator approach to cancer therapy

    Suzanne L. Topalian;Charles G. Drake;Drew M. Pardoll

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

    Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

  • A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

    James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu

  • Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

    S A Rosenberg;B S Packard;P M Aebersold;D Solomon

  • Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

    Suzanne L. Topalian;Janis M. Taube;Robert A. Anders;Drew M. Pardoll

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

    Janis M Taube;Alison P. Klein;Julie R Brahmer;Haiying Xu

  • Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

    Janis M. Taube;Robert A. Anders;Geoffrey D. Young;Haiying Xu

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

    Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou

  • Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

  • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

    Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  • Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.

    James C. Yang;Alfred E. Chang;Alan R. Baker;William F. Sindelar

  • Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

    Eric V. Dang;Joseph Barbi;Huang Yu Yang;Huang Yu Yang;Dilini Jinasena

  • Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction

    Steven A. Rosenberg;Paul Aebersold;Kenneth Cornetta;Attan Kasid

  • Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

    Suzanne L Topalian;Charles G Drake;Drew M Pardoll

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Janis M. Taube
Janis M. Taube Johns Hopkins University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Douglas J. Schwartzentruber
Douglas J. Schwartzentruber National Institutes of Health
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Robert A. Anders
Robert A. Anders Johns Hopkins University School of Medicine
Drew M. Pardoll
Drew M. Pardoll Johns Hopkins University School of Medicine
Mario Sznol
Mario Sznol Yale University
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Charles G. Drake
Charles G. Drake Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related healthcare degrees can open doors to diverse, rewarding careers. Many immunology graduates find transitioning into nursing or advanced practice roles attractive, offering hands-on patient care and leadership opportunities.

Several programs can accelerate this career shift. For instance, 12-month accelerated nursing programs online for non nurses allow students from non-nursing backgrounds to enter the nursing field swiftly, gaining essential clinical skills in a condensed timeframe.

Once in nursing, professionals might pursue specialized pathways. accelerated nurse practitioner programs offer intensive curricula that prepare graduates for advanced practice roles, including acute care settings.

Specifically, those interested in acute patient management can explore acute care nurse practitioner programs, designed for family nurse practitioners aiming to expand their expertise in high-acuity environments.

Considering specialization is also vital for career growth and salary potential. Information on the highest paid dnp specialties can guide professionals seeking to maximize their earning opportunities while making impactful contributions in healthcare.

Best Scientists Citing Suzanne L. Topalian

Trending Scientists

Recently Published Articles